Saint-Herblain (FRANCE) – September 22, 2011 - Algenics, the biopharmaceutical company offering a unique microalgae-based solution for the development of recombinant biotherapeutics, announced that it has obtained a €150 000 Participative Priming Loan (“Prêt Participatif d’Amorçage”) granted by OSEO, the French innovation agency, with the support of Région Pays de la Loire.
“Through this loan dedicated to innovative SMEs, we are pleased with the renewed support of OSEO. It will help strengthen the company’s R&D efforts and will create favourable conditions for the opening of the capital to future investors” explained Aude Carlier, CEO & CSO of Algenics.
About ALGENICS:
Algenics S.A.S is a privately-held biopharmaceutical company founded in 2008 and operating its own facility in Saint-Herblain /Nantes (FRANCE).
The company develops recombinant therapeutics for human health by leveraging a unique microalgae-based technology. Our platform AlgebiosysTM encompasses tools to efficiently generate stable strains of microalgal cells with high-level of safety. This proprietary and patented platform allows the biomanufacturing of a broad range of therapeutics in our PTA cell line including complex multimeric glycoproteins.
Our strategy is to develop biotherapeutics that benefit from our technologies. Our targets include recombinant products with enhanced biological activities for application in oncology and virology.
For more information please visit our website:
www.algenics.com
Contact
Alexandre Lejeune
Business Development Manager
Algenics, Pôle Bio Ouest, rue du Moulin Rousselière
44800 Saint-Herblain, France
T: +33 2 40 40 75 22 • F: +33 2 40 59 32 44
DOWNLOAD THE PDF FILE / TELECHARGER LE FICHIER PDF
